News

Eric Segal, MD, director of pediatric epilepsy, HMH Hackensack University Medical Center, detailed his study on diazepam nasal spray in patients with and without antiseizure medications.

Patients with any presence of small vessel disease had a 2-times greater risk of recurrent ischemic stroke than those without.

Data used from the ENSEMBLE PLUS study showed a comparable frequency of infusion reactions between those who received the 2-hour infusion and the 3.5-hour infusion.

The novel gold nanocrystal suspension has also been shown to remyelinate chronic MS lesions.

After a sudden reversal and complex analyses, aducanumab’s future rests in the hands of the FDA while the community stands split on if the available data are enough to justify an approval.

The StrokeViewer tool is currently in use in Australia and Europe and has led to reduced patient disability in the short-term and more clot removals performed.

The pediatric neurologist at Montefiore Health System explains the importance of treating infantile spasms as early as possible and how it may impact outcomes.

Future studies are necessary to determine whether longer treatment of ezogabine can sustain the effects on excitability and slow disease progression.

Here's what is coming soon to NeurologyLive.

MDS-UPDRS score improvements from baseline were significantly greater in patients using the Personal KinetiGraph.

Kelly Knupp, MD, pediatric neurologist and epilepsy specialist, Children’s Hospital Colorado, detailed the findings of fenfluramine in patients with Lennox-Gastaut syndrome and how it may shake up the treatment landscape.

The neurologist at the Barrow Neurological Institute gave her thoughts on how telemedicine has evolved throughout this year and its potential moving forward.

Neurology News Network for the week ending December 12, 2020.

Pimavanserin (Nuplazid; Acadia) is indicated for hallucinations and delusions associated with Parkinson disease psychosis, and the capsules can now be emptied onto food for patients with swallowing issues.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 11, 2020.

Seizure reduction was observed to be sustained for up to 192 weeks in the Expanded Access Program data.

Treatment effects in favor of digital cognitive behavioral therapy were observed for insomnia severity, sleep efficiency, cognitive failures, fatigue, sleepiness, depression, and anxiety.

The neurologist from Universitätsmedizin Berlin and Berlin Institute of Health spoke about his study presented at AES 2020 and how the next steps following the positive results.

No cognitive improvements were observed for exercise versus waitlist groups of cognitively normal patients with MS.

The US Early Access Program for fenfluramine allowed access to the treatment for patients who were ineligible for clinical trials.

Patients receiving perampanel in combination with an enzyme-inducing anti-seizure medication may require a higher perampanel dose to achieve similar efficacy with only non-EIASMs.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how patients found cenobamate effective for up to 43 months.

Further results of the 2 phase 3 studies are expected to be completed and presented in detail in first half of 2021, with a BLA submission to follow.

Michael Okun, MD, executive director of the Norman Fixel Institute for Neurological Diseases detailed the collaborative effort needed to see sustainable change in the approval system of neurological devices.

Study data from the NIH/CDC Sudden Death in the Young (SDY) Case Registry suggest that nonwhite children and infants have rates of SUDEP mortality 1.5 times higher than whites.

Microburst stimulation was also found to be more tolerable than standard stimulation in patients with drug-resistant epilepsy.

The director of pediatric epilepsy at HMN Hackensack University Medical Center provided background on how his data may change how clinicians use diazepam nasal spray.

Christian Meisel, MD, PhD, department of neurology, Universitätsmedizin Berlin, and Berlin Institute of Health, discussed the landscape for devices that forecast seizures, including the use of multi-modal wristband sensors.